Clinical Trials in Cleveland

Showing 11461-11480 of 16,969 trials

Remission and Flare in Psoriatic Arthritis: a Prospective 6-month Study With a Double Perspective.

NCT03119805

The purpose of this study is to define cut-off values of the most widely used composite scores and patient-reported outcomes, for levels corresponding to remission/low disease activity and for changes in levels corresponding to flares, in PsA, when remission/low disease activity and flare are defined from the patient and physician perspective. The ReFlaP (Remission/Flare in PsA) study is a prospective, multicentric international, longitudinal, observational study.

Psoriatic Arthritis

Groupe Hospitalier Pitie-Salpetriere466 participantsStarted May 2017

Baltimore, Maryland, United States • Cleveland, Ohio, United States • Vienna, Austria +19 more locations

COMPLETEDPhase 2< 1 mile

An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis

NCT02601300

This is a phase 2, open-label, multicenter study to explore the efficacy and safety of oral GED- 0301 in subjects with active UC, defined as a modified Mayo score (MMS) ≥ 4 and ≤ 9 and a Mayo endoscopic subscore≥ 2. Approximately 40 subjects will be enrolled using an Interactive Voice Response System (IVRS) or an Interactive Web Response System (IWRS) to receive open-label, oral GED-0301 160 mg for duration of 52 week treatment. Enrollment of subjects with previous exposure to TNF-α blockers will be limited to approximately 15 subjects. The number of subjects with extensive colitis is targeted to comprise approximately 50% of the entire study population.

Colitis, Ulcerative

Celgene41 participantsStarted Dec 2015

Newport Beach, California, United States • San Diego, California, United States • Gainesville, Florida, United States +33 more locations

Remission and Flare in Psoriatic Arthritis: a Prospective 6-month Study With a Double Perspective.

An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis

Find Trials by Condition in Cleveland

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza

Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults

Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas

Triathlon® Cruciate Retaining (CR) Total Knee System Outcomes Study

Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy

Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma

Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery

Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection

Markers of Pubertal Suppression During Therapy for Precocious Puberty

Sunitinib Non Small Cell Lung Cancer Patients Over 70

Sym004 in Patients With Advanced Solid Tumors